Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.51 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.51 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464373 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL15489111 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL5311408 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL15489112 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL6685329 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL24696627 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13818478 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL5316339 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13818477 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13713744 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372395-A1 | CAR CELLS TARGETING AN INSERTED LIGAND | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023224715-A1 | CAR CELLS TARGETING AN INSERTED LIGAND | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11766481-B2 | Glycan modified short interfering RNA | GANNA BIO, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| EP-4204441-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-20220049237-A1 | CARRIER FOR ENZYME IMMOBILIZATION USE, AND IMMOBILIZED ENZYME | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2022-02-17 | — | — | US | disclosed |
| US-20160303184-A1 | VANCOMYCIN-SUGAR CONJUGATES AND USES THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENT RES (JNCASR) (IN) | 2016-10-20 | — | — | US | disclosed |
| WO-2015040467-A1 | VANCOMYCIN-SUGAR CONJUGATES AND USES THEREOF | Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) (IN) | 2015-03-26 | — | — | WO | disclosed |
| EP-1200484-B1 | METHODS AND REAGENTS MAKING MULTIVALENT ARRAYS AND COMBINATORIAL LIBRARIES OF MULTIVALENT ARRAYS | WISCONSIN ALUMNI RES FOUND (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-1337229-B1 | IMMOBILISATION OF ACTIVE AGENTS ON FIBRES | HENKEL AG & CO KGAA (DE) | 2009-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303184-A1 | VANCOMYCIN-SUGAR CONJUGATES AND USES THEREOF | SLC5A2, SLC5A1, SI | IGF2R 305/4885GAA 108/4885LGALS8 405/4885 |
| US-11766481-B2 | Glycan modified short interfering RNA | SNRPE, FUT6, ALG8 | IGF2R 112/4885GAA 171/4885LGALS8 65/4885 |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | IGF2R 315/4885GAA 86/4885LGALS8 78/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | IGF2R 29/4885GAA 4062/4885LGALS8 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.